Chi-Fen Chuang

Chi-Fen Chuang

Auto-generated profile, based on publicly available information

Chi-Fen Chuang

Graduate Institute of Biomedical Sciences, China Medical University, Taichung 404328, Taiwan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2022 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
MCMao-Lin Chen
Mao-Lin Chen
TYTa-Tung Thomas Yuan
Ta-Tung Thomas Yuan
CCChi-Fen Chuang
Chi-Fen Chuang
YHYung-Tsang Huang
Yung-Tsang Huang
ICI Che Chung
I Che Chung
WHWei-Ching Huang
Wei-Ching Huang
Prostate cancer is one of the most common causes of cancer death in men worldwide, and the treatment options are limited for patients with advanced stages of prostate cancer. Upon oncogenic or inflammatory stimulation, tumor cells or immune cells express cell surface enolase-1 (ENO1) as plasminogen receptor to facilitate their migration via plasmin activation. Little is known about the roles of ENO1 in prostate cancer, especially in the tumor microenvironment (TME). We hypothesized that targeting surface ENO1 with specific mAbs would exert multifactorial therapeutic potentials against prostate cancer. In vivo, we showed ENO1 mAb (HuL227) reduced the growth of subcutaneous PC-3 xenograft, monocytes recruitment, and intratumoral angiogenesis. In a PC-3 intratibial implantation model, HuL227 reduced tumor growth and osteoclast activation in the bone. To investigate the antitumor mechanism of ENO1 mAb, we found that blocking surface ENO1 significantly reduced VEGF-A–induced tube formation of endothelial cells in vitro. Furthermore, HuL227 inhibited inflammation-enhanced osteoclasts activity and the secretion of invasion-related cytokines CCL2 and TGFβ from osteoclasts. In addition, inflammation-induced migration and chemotaxis of androgen-independent prostate cancer cells were dose-dependently inhibited by HuL227. In summary, we showed that, ENO1 mAb targets multiple TME niches involved in prostate cancer progression and bone metastasis via a plasmin-related mechanism, which may provide a novel immunotherapy approach for men with advanced prostate cancer.

23 June 2022 in Cancers
Verified
Journal Article
Open access
PDF file
JCJung Ying Chiang
Jung Ying Chiang
FLFu-Ju Lei
Fu-Ju Lei
HCHuan-Jui Chang
Huan-Jui Chang
SWSung-Tai Wei
Sung-Tai Wei
CWChi-Chung Wang
Chi-Chung Wang
CHChia-Hung Hsieh
Chia-Hung Hsieh
Haloperidol is a routine drug for schizophrenia and palliative care of cancer; it also has antitumor effects in several types of cancer. However, the role of haloperidol in endometrial cancer (EC) development is still unclear. Here, we show that chronic haloperidol treatment in clinically relevant doses induced endometrial hyperplasia in normal mice and promoted tumor growth and malignancy in mice with orthotopic EC. The pharmacokinetic study indicated that haloperidol highly accumulated in the uterus of mice. In vitro studies revealed that haloperidol stimulated the cellular transformation of human endometrial epithelial cells (HECCs) and promoted the proliferation, migration, and invasion of human endometrial carcinoma cells (HECCs) by activating nuclear factor kappa B (NF-κB) and its downstream signaling target, colony-stimulating factor 1 (CSF-1). Gain of function of CSF-1 promotes the cellular transformation of HEECs and the malignant progression of HECCs. Moreover, blockade of CSF-1 inhibited haloperidol-promoted EC progression in vitro and in vivo. A population-based cohort study of EC patients further demonstrated that the use of haloperidol was associated with increased EC-specific mortality. Collectively, these findings indicate that clinical use of haloperidol could potentially be harmful to female patients with EC.

3 April 2023
Verified
Other
Open access
MCMao-Lin Chen
Mao-Lin Chen
TYTa-Tung Thomas Yuan
Ta-Tung Thomas Yuan
CCChi-Fen Chuang
Chi-Fen Chuang
YHYung-Tsang Huang
Yung-Tsang Huang
ICI Che Chung
I Che Chung
WHWei-Ching Huang
Wei-Ching Huang
Supplementary Figure from A Novel Enolase-1 Antibody Targets Multiple Interacting Players in the Tumor Microenvironment of Advanced Prostate Cancer

3 April 2023
Verified
Other
Open access
MCMao-Lin Chen
Mao-Lin Chen
TYTa-Tung Thomas Yuan
Ta-Tung Thomas Yuan
CCChi-Fen Chuang
Chi-Fen Chuang
YHYung-Tsang Huang
Yung-Tsang Huang
ICI Che Chung
I Che Chung
WHWei-Ching Huang
Wei-Ching Huang
Supplementary Figure from A Novel Enolase-1 Antibody Targets Multiple Interacting Players in the Tumor Microenvironment of Advanced Prostate Cancer

3 April 2023
Verified
Other
Open access
MCMao-Lin Chen
Mao-Lin Chen
TYTa-Tung Thomas Yuan
Ta-Tung Thomas Yuan
CCChi-Fen Chuang
Chi-Fen Chuang
YHYung-Tsang Huang
Yung-Tsang Huang
ICI Che Chung
I Che Chung
WHWei-Ching Huang
Wei-Ching Huang
Prostate cancer is one of the most common causes of cancer death in men worldwide, and the treatment options are limited for patients with advanced stages of prostate cancer. Upon oncogenic or inflammatory stimulation, tumor cells or immune cells express cell surface enolase-1 (ENO1) as plasminogen receptor to facilitate their migration via plasmin activation. Little is known about the roles of ENO1 in prostate cancer, especially in the tumor microenvironment (TME). We hypothesized that targeting surface ENO1 with specific mAbs would exert multifactorial therapeutic potentials against prostate cancer. In vivo, we showed ENO1 mAb (HuL227) reduced the growth of subcutaneous PC-3 xenograft, monocytes recruitment, and intratumoral angiogenesis. In a PC-3 intratibial implantation model, HuL227 reduced tumor growth and osteoclast activation in the bone. To investigate the antitumor mechanism of ENO1 mAb, we found that blocking surface ENO1 significantly reduced VEGF-A–induced tube formation of endothelial cells in vitro. Furthermore, HuL227 inhibited inflammation-enhanced osteoclasts activity and the secretion of invasion-related cytokines CCL2 and TGFβ from osteoclasts. In addition, inflammation-induced migration and chemotaxis of androgen-independent prostate cancer cells were dose-dependently inhibited by HuL227. In summary, we showed that, ENO1 mAb targets multiple TME niches involved in prostate cancer progression and bone metastasis via a plasmin-related mechanism, which may provide a novel immunotherapy approach for men with advanced prostate cancer.

3 April 2023
Verified
Other
Open access
MCMao-Lin Chen
Mao-Lin Chen
TYTa-Tung Thomas Yuan
Ta-Tung Thomas Yuan
CCChi-Fen Chuang
Chi-Fen Chuang
YHYung-Tsang Huang
Yung-Tsang Huang
ICI Che Chung
I Che Chung
WHWei-Ching Huang
Wei-Ching Huang
Supplementary Figure from A Novel Enolase-1 Antibody Targets Multiple Interacting Players in the Tumor Microenvironment of Advanced Prostate Cancer